| Name | Title | Contact Details |
|---|
At Galileo Life, our goal is nothing short of a revolution in the way that healthcare is talked about and delivered. Through the establishment of a dedicated and professional network of Galileo Smart Clinics throughout the country, our vision is the development of a national-level holistic health services and wellness platform specializing in assessment, diagnostic, home-monitoring, and treatment services. The Healthcare Renaissance is here, and Galileo Life Sciences intends to herald the change in Healthcare and re-imagine Healthcare options. Galileo Life Sciences is about the pursuit of alternative solutions both in addition to, and outside of the current Western medical healthcare paradigm. We believe in taking the best of the conventional and combining it with what nature has provided - and what droves of scientific research continues to uncover and confirm - to help us heal, relieve pain, improve sleep, alleviate anxiety, increase appetite, offset the side effects of powerful pharmacological and medical treatments, and much more. Galileo Life Sciences extends an invitation to all practitioners and entrepreneurs in the Healthcare sector, to join us and become part of the bold and rapid global movement to ensure that healthcare is accessible by all in the world.
Rezolute is a clinical stage biopharmaceutical company specializing in the development of innovative drug therapies to improve the lives of patients with metabolic and orphan diseases.
Light House Ministries is a Lake Bluff, IL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Avicanna is a diversified and vertically integrated Canadian bio-pharmaceutical company focused on the research, development and commercialization of plant-derived cannabinoid-based products for the global consumer, medical, and pharmaceutical market segments. Avicanna is an established leader in cannabinoid research and development, which it primarily conducts at its R&D headquarters in the Johnson & Johnson Innovation Centre, JLABS @ Toronto, Canada and in collaboration with leading Canadian academic and medical institutions. In addition to its developing pharmaceutical pipeline, Avicanna`s team of experts have developed and commercialized several industry leading product lines, including: Pura H&W™: an advanced and clinically tested line of CBD consumer derma-cosmetic products; and, RHO Phyto™: an advanced line of medical cannabis products containing varying ratios of CBD and THC currently available nation-wide across Canada in partnership with Medical Cannabis by Shoppers™, a subsidiary of Shoppers Drug Mart. RHO Phyto is the first strictly medical formulary of advanced “Cannabis 2.0” products, containing oils, sprays, capsules, creams, and gels, all developed with scientific rigour, manufactured under GMP standards and supported by pre-clinical data. With ongoing clinical trials on its medical cannabis (RHO Phyto) and a pipeline of pharmaceutical products, Avicanna`s dedication to researching the important role that cannabinoids play in an increasingly wider scope of products has been at the core of the Company`s vision since its inception. Avicanna manages its own supply chain including cultivation and extraction through its two majority-owned subsidiaries, Sativa Nativa S.A.S. and Santa Marta Golden Hemp S.A.S., both located in Santa Marta, Colombia. Through these sustainable, economical, and industrial scale subsidiaries, Avicanna cultivates, processes, and commercializes a range of cannabis and hemp derived API and custom formulations.
Federation Bio is a biotechnology company pioneering a novel approach to create potent, durable and safe cell therapies. The company`s first-in-class platform combines the power of genetic engineering and synthetic consortium design to control systemic immune responses and broad metabolic functions. Federation Bio`s pipeline addresses a range of serious illnesses from metabolic disorders to metastatic cancer. The company`s lead program is in enteric hyperoxaluria, a serious renal condition that affects more than 250,000 Americans and for which there are currently no approved therapies.